王茜博士為國家級海外高層次人才青年項目獲得者，將于2025年5月全職加入武漢大學，任生命科學學院教授、高致病性病毒與生物安全國家重點實驗室教授、泰康生命醫學中心教授，博士生導師。王茜博士于2018年獲得清華大學博士學位，隨后在哈佛大學 Joseph G. Sodroski 教授實驗室開展博士后研究，并在哥倫比亞大學何大一教授（Dr. David Ho）實驗室擔任高級副研究員（Associate Research Scientist）。自2024年5月至2025年4月，任美國哥倫比亞大學助理教授（Assistant Professor），并曾榮獲2023年度《麻省理工科技評論》（MIT Technology Review）“35歲以下科技創新35人（Innovators Under 35）中國區入選者”。

聯合實驗室的另一位導師為劉立鴻博士，國家級海外高層次人才青年項目獲得者。劉立鴻博士已于2024年5月全職加入武漢大學，現任武漢大學生命科學學院教授、高致病性病毒與生物安全國家重點實驗室教授、泰康生命醫學中心教授。劉立鴻博士于2015年在中國科學院上海巴斯德研究所獲得博士學位，隨后在美國洛克菲勒大學艾倫·戴蒙德艾滋病研究中心何大一教授（Dr. David Ho）課題組開展博士后研究。2021年至2024年，任美國哥倫比亞大學助理教授（Assistant Professor）。劉立鴻博士科研成果突出，2025年榮獲首屆Wiley新銳科學家獎。

王茜博士與劉立鴻博士在冠狀病毒（包括新冠）和艾滋病研究領域取得了一系列突出成果，分別以第一作者或通訊作者身份在Nature（6 篇）、Cell、New England Journal of Medicine（NEJM，2 篇）、The Lancet、Immunity、Science Translational Medicine、Cell Host & Microbe（2 篇）、Cell Reports（3 篇）、Cell Reports Medicine（2 篇）、The Lancet Infectious Diseases（4 篇）、Journal of Virology（5 篇）等國際著名期刊發表研究論文。兩位學者的研究成果在學術界產生廣泛影響，谷歌學術總引用超過 16,500 次。

聯合實驗室將聚焦重大傳染性疾病對公共衛生安全的影響，帶領團隊開展病毒進化、感染機制及人體體液免疫應答等方向的研究，致力于揭示病毒長期演化與公共健康風險之間的內在聯系。因課題組發展需要，現誠摯歡迎對相關研究方向感興趣的有志之士加入我們的聯合團隊，共同推動科學發現與技術轉化。

招聘流程及要求

現招聘科研助理和博士后！誠摯歡迎感興趣的有志之士加入聯合團隊，有意者請將以下材料發送至：llh3411@whu.edu.cn。郵件標題請注明“應聘崗位名稱+姓名”。初審通過后，將通知安排面試，擇優錄取。應聘材料將予以保密。

1. 個人簡歷，包括學習工作經歷、主要研究方向、代表性論文論著清單、獲獎情況。

2. 學歷學位證書、身份證掃描件。

3. Cover letter: 簡要介紹既往工作、研究興趣和職業規劃。

4. 申請人認為其他有借鑒意義的材料。

5.兩封推薦信，包括碩士或博士導師推薦信一封。推薦信應由推薦人郵箱直接發出。

科研助理：

1. 生物學相關專業本科或碩士，具有良好的英文讀寫能力；

2. 團隊管理能力；

3.根據武漢大學相關規定以及個人工作能力，提供具有競爭力的薪酬待遇，具體薪資面談。

博士后：

1. 已獲得或即將獲得生命科學相關專業博士學位，有病毒學、生物信息學、免疫學、疫苗學、結構生物學等相關研究背景者優先；

2. 具有良好的中英文寫作能力，以第一作者身份在國際權威期刊發表過原創性研究論文；

3. 身心健康，為人誠信，樂于團隊協作，具有獨立開展科研工作的能力。

4. 具體待遇一人一議，請參考武漢大學博士后管理規定：

https://mp.weixin.qq.com/s/OcpHJtxaGg_wWazeXxlV7Q

該招聘長期有效，招滿為止。

代表性發表的論文：（*第一作者，#通訊作者）

1.Wang Q, Guo Y, Mellis IA, Wu M, Mohri H, Gherasim C, Valdez R, Purpura LJ, Yin MT, Gordon A, Ho DD. Antibody evasiveness of SARS-CoV-2 subvariants KP.3.1.1 and XEC.Cell Reports. 2025 Apr 8;44(4):115543. doi: 10.1016/j.celrep.2025.115543.

2.Wang Q, Mellis IA, Wu M, Bowen A, Gherasim C, Valdez R, Shah JG, Purpura LJ, Yin MT, Gordon A, Guo Y, Ho DD. KP.2-based monovalent mRNA vaccines robustly boost antibody responses to SARS-CoV-2.The Lancet Infectious Diseases2025 Feb 4:S1473-3099(25)00058-1.

3.Wang Q, Guo Y, Ho J, Ho DD. Activity of Research-Grade Pemivibart against Recent SARS-CoV-2 JN.1 Sublineages.New England Journal of Medicine2024 Nov 14;391(19):1863-1864.

4.Wang Q, Mellis IA, Ho J, Bowen A, Kowalski-Dobson T, Valdez R, Katsamba PS, Wu M, Lee C, Shapiro L, Gordon A, Guo Y, Ho DD,Liu L#. Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineages.Emerging Microbes & Infections2024 Sep 11:2402880.

5.Wang Q,Mellis IA, Guo Y, Gherasim C, Valdez R, Gordon A, Ho DD,Liu L#. Robust SARS-CoV-2-neutralizing antibodies sustained through 6 months post XBB.1.5 mRNA vaccine booster.Cell Reports Medicine2024 Aug 23:101701.

6.Wang Q, Guo Y, Bowen A, Mellis IA, Valdez R, Gherasim C, Gordon A,Liu L#, Ho DD. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against emerging SARS-CoV-2 variants.Cell Host & Microbe2024 Mar 13;32(3):315-321.e3.

7.Wang Q, Guo Y, Schwanz LT, Mellis IA, Sun Y, Qu Y, Urtecho G, Valdez R, Stoneman E, Gordon A, Wang HH, Ho DD,Liu L#. SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1.Emerging Microbes & Infections2024 Dec;13(1):2359004.

8.Wang Q, Zhang S, Nguyen HT, Sodroski JG. Inhibition of human immunodeficiency virus (HIV-1) infectivity by expression of poorly or broadly neutralizing antibodies against Env in virus-producing cells.Journal of Virology2024 Feb 20;98(2):e0159423.

9.Liu L*,#, Casner RA*, Guo Y*,Wang Q*, Iketani S, Chan JFW, Yu J, Dadonaite B, Nair MS, Mohri H, Reddem ER, Yuan S, Poon VK, Chan CC, Yuen KY, Sheng Z, Huang Y, Bloom JD, Shapiro L, Ho DD. Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking.Immunity. 2023 Oct 10;56(10):2442-2455.e8.

10.Wang Q, Guo Y, Liu L, Schwanz LT, Li Z, Nair MS, Ho J, Zhang RM, Iketani S, Yu J, Huang Y, Qu Y, Valdez R, Lauring AS, Huang Y, Gordon A, Wang HH,Liu L#, Ho DD. Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike.Nature2023 Dec;624(7992):639-644.

11.Wang Q, Guo Y, Tam AR, Valdez R, Gordon A,Liu L#, Ho DD. Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine.Cell Reports Medicine2023 Nov 21;4(11):101258.

12.Wang Q, Bowen A, Ho J, Zhang RM, Valdez R, Stoneman E, Gordon A,Liu L#, Ho DD. SARS-CoV-2 neutralising antibodies after a second BA.5 bivalent booster.Lancet2023 Nov 18;402(10415):1827-1828.

13.Wang Q, Guo Y, Zhang RM, Ho J, Mohri H, Valdez R, Manthei DM, Gordon A,Liu L#, Ho DD. Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6.The Lancet Infectious Diseases2023 Oct;23(10):e397-e398.

14.Wang Q, Li Z,Guo Y, Mellis IA, Iketani S, Liu M, Yu J, Valdez R, Lauring AS, Sheng Z, Gordon A,Liu L#, Ho DD. Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2.iScience2023 Oct 18;26(11):108254.

15. Zhang Z*,Wang Q*, Nguyen HT, Smith AB, Sodroski JG. Alterations in gp120 Glycans or the gp41 Fusion Peptide-Proximal Region Modulate the Stability of the Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Pretriggered Conformation.Journal of Virology2023 Sep 28;97(9):e0059223.

16.Wang Q,Bowen A, Tam AR, Valdez R, Stoneman E, Mellis IA, Gordon A,Liu L#, Ho DD. SARS-CoV-2 Neutralizing Antibodies After Bivalent vs. Monovalent Booster.The Lancet Infectious Diseases2023 May;23(5):527-528.

17.Wang Q, Yeh AY, Guo Y, Mohri H, Yu J, Ho DD,Liu L#. Impaired potency of neutralizing antibodies against cell-cell fusion mediated by SARS-CoV-2.Emerging Microbes & Infections2023 May 3:2210237.

18.Wang Q,Bowen A, Valdez R, Gherasim C, Gordon A,Liu L#, Ho DD. Antibody Response to Omicron BA.4-BA.5 Bivalent Booster.New England Journal of Medicine2023 Feb 9;388(6):567-569.

19.Wang Q, Iketani S, Li Z, Liu L, Guo Y, Huang Y, Bowen AD, Liu M, Wang M, Yu J, Valdez R, Lauring AS, Sheng Z, Wang HH, Gordon A,Liu L#, Ho DD. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.Cell2023 Jan 19;186(2):279-286.e8.

20.Liu L, Iketani S, Guo Y, Reddem ER, Casner RG, Nair MS, Yu J, Chan JF, Wang M, Cerutti G, Li Z, Morano NC, Castagna CD, Corredor L, Chu H, Yuan S, Poon VK, Chan CC, Chen Z, Luo Y, Cunningham M, Chavez A, Yin MT, Perlin DS, Tsuji M, Yuen KY, Kwong PD, Sheng Z, Huang Y, Shapiro L & Ho DD. An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses.Science translational medicine. 2022; 14(646):eabn6859.

21. Iketani S*,Liu L*, Guo Y*, Liu L*, Chan JF*, Huang Y, Wang M, Luo Y, Yu J, Chu H, Chik KK, Yuen TT, Yin MT, Sobieszczyk ME, Huang Y, Yuen KY, Wang HH, Sheng Z & Ho DD. Antibody evasion properties of SARS-CoV-2 Omicron sublineages.Nature2022; 604(7906):553-6.

22.Liu L, Iketani S, Guo Y, Chan JF, Wang M, Liu L, Luo Y, Chu H, Huang Y, Nair MS, Yu J, Chik KK, Yuen TT, Yoon C, To KK, Chen H, Yin MT, Sobieszczyk ME, Huang Y, Wang HH, Sheng Z, Yuen KY & Ho DD. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2.Nature2022; 602(7898):676-81.

23.Wang Q, Li Z, Ho J, Guo Y, Yeh AY, Liu M, Wang M, Yu J, Sheng Z, Huang Y,Liu L#, Ho DD. Resistance of SARS-CoV-2 Omicron Subvariant BA.4.6 to Antibody Neutralization.The Lancet Infectious Diseases2022 Oct 31:S1473-3099(22)00694-6.

24.Wang Q, Iketani S, Li Z, Guo Y, Yeh AY, Liu M, Yu J, Sheng Z, Huang Y,Liu L#, Ho DD. Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75.Cell Host & Microbe2022 Sep 6:S1931-3128(22)00419-X.

25.Wang Q, Guo Y, Iketani S, Nair MS, Li Z, Mohri H, Wang M, Yu J, Bowen AD, Chang JY, Shah JG, Nguyen N, Chen Z, Meyers K, Yin MT, Sobieszczyk ME, Sheng Z, Huang Y,Liu L#, Ho DD. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5.Nature2022 Aug;608(7923):603-608.

26.Wang Q*,#, Anang S*, Iketani S, Guo Y, Liu L, Katsamba PS, Shapiro L, Ho DD, Sodroski JG#. Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529.Cell Reports2022 Jun 14;39(11):110924.

27.Wang Q, Esnault F, Zhao M, Chiu TJ, Smith AB, Nguyen HT, Sodroski JG. Global Increases in Human Immunodeficiency Virus Neutralization Sensitivity Due to Alterations in the Membrane-Proximal External Region of the Envelope Glycoprotein Can be Minimized by Distant State 1-Stabilizing Changes.Journal of Virology2022 Mar 15;e0187821.

28. Wang P*, Nair MS*,Liu L*, Iketani S*, Luo Y, Guo Y, Wang M, Yu J, Zhang B, Kwong PD, Graham BS, Mascola JR, Chang JY, Yin MT, Sobieszczyk M, Kyratsous CA, Shapiro L, Sheng Z, Huang Y, and Ho DD. Nature 2021; Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7.Nature2021;593, 130-135.

29.Wang Q, Nair MS, Anang S, Zhang S, Nguyen H, Huang Y, Liu L, Ho DD, Sodroski JG. Functional differences among the spike glycoproteins of multiple emerging severe acute respiratory syndrome coronavirus 2 variants of concern.iScience2021; Nov 19;24(11):103393.

30.Liu L, Wang P, Nair MS, Yu J, Rapp M, Wang Q, Luo Y, Chan JF, Sahi V, Figueroa A, Guo XV, Cerutti G, Bimela J, Gorman J, Zhou T, Chen Z, Yuen KY, Kwong PD, Sodroski JG, Yin MT, Sheng Z, Huang Y, Shapiro L and Ho DD. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.Nature2020; 584(7821): 450-456.

31.Wang Q, Ma B, Liang Q, Zhu A, Wang H, Fu L, Han X, Shi X, Xiang Y, Shang H and Zhang L. Stabilized diverse HIV-1 envelope trimers for vaccine design.Emerging Microbes & Infections2020 Dec;9(1):775-786.

32.Wang Q, Finzi A and Sodroski JG. The Conformational States of the HIV-1 Envelope Glycoproteins.Trends in Microbiology2020 Aug;28(8):655-667.

33.Liu L, Wang P*,Nair MS*, Yu J*, Rapp M*,Wang Q*, Luo Y, Chan JF, Sahi V, Figueroa A, Guo XV, Cerutti G, Bimela J, Gorman J, Zhou T, Chen Z, Yuen KY, Kwong PD, Sodroski JG, Yin MT, Sheng Z, Huang Y, Shapiro L and Ho DD. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.Nature2020 Aug;584(7821):450-456.

文章發表情況詳見：

1. https://scholar.google.com/citations?hl=en&user=p3szl5IAAAAJ

2.https://scholar.google.com/citations?user=VLggvyoAAAAJ&hl=en